The United States launches a new trade investigation into Germany’s pharmaceutical pricing policies under Section 301 of the Trade Act, according to multiple outlets. The Office of the U.S. Trade Representative says the issue is Germany’s alleged “persistent underpayment for innovative pharmaceutical products,” which it argues burdens U.S. commerce. USTR Jamieson Greer also criticizes a German proposal aimed at reducing spending on medicines, describing it as a step backwards. The investigation can lead to trade retaliation measures, including potential tariffs or other levies on German goods, if USTR concludes that Germany’s practices are unfair and harmful to U.S. interests.
German officials and the broader German policy context are noted in reporting: Germany is described as seeking to control insurer drug costs by adjusting medicine spending and pricing approaches. The investigation’s outcome will determine whether the U.S. moves from inquiry to specific penalties. Across coverage, the central shared point is the U.S. claim that Germany’s pricing practices disadvantage innovative pharmaceutical products and trigger possible tariff actions once the review is completed.
